How clinical development can, and should, inform translational science

Neuron

Volumn 84, Issue 3, 2014, Pages 582-593

  Barker Haliski, Melissa ^a   Friedman, Daniel ^b   White, H Steve ^a   French, Jacqueline A ^b  

^a UNIVERSITY OF UTAH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CARBAMAZEPINE; CARISBAMATE; ETIRACETAM; HUPERZINE A;

ADVERSE OUTCOME; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CEREBROVASCULAR ACCIDENT; CLINICAL DEVELOPMENT PLAN; CLINICAL EVALUATION; CLINICAL STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EPILEPSY; FOCAL EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; NEUROPROTECTION; NONHUMAN; NUMBERS NEEDED TO TREAT; REVIEW; RISK REDUCTION; SEIZURE; TIME TO TREATMENT; TONIC CLONIC SEIZURE; TRANSLATIONAL RESEARCH; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT INDICATION; ANIMAL; CLINICAL TRIAL (TOPIC); MENTAL DISORDERS; NERVOUS SYSTEM DISEASES;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84912116891     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.10.029     Document Type: Review

References (79)

1. Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr. Dis. Treat. 2008, 4:507-523.
2. Annegers J.F., Hauser W.A., Shirts S.B., Kurland L.T. Factors prognostic of unprovoked seizures after febrile convulsions. N.Engl. J. Med. 1987, 316:493-498.
3. Annegers J.F., Hauser W.A., Coan S.P., Rocca W.A. A population-based study of seizures after traumatic brain injuries. N.Engl. J. Med. 1998, 338:20-24.
4. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators.
5. Barton M.E., Klein B.D., Wolf H.H., White H.S. Pharmacological characterization of the 6Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001, 47:217-227.
6. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007, 26:1-13.
7. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., Dilitz E., Deisenhammer F., Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N.Engl. J. Med. 2003, 349:139-145.
8. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009, 83:1-43.
9. Blesa J., Phani S., Jackson-Lewis V., Przedborski S. Classic and new animal models of Parkinson's disease. J.Biomed. Biotechnol. 2012, 2012:845618.
10. Bohbot V.D., Kalina M., Stepankova K., Spackova N., Petrides M., Nadel L. Spatial memory deficits in patients with lesions to the right hippocampus and to the right parahippocampal cortex. Neuropsychologia 1998, 36:1217-1238.
11. Bouilleret V., Ridoux V., Depaulis A., Marescaux C., Nehlig A., Le Gal La Salle G. Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy. Neuroscience 1999, 89:717-729.
12. Brodie M.J., Kwan P. Staged approach to epilepsy management. Neurology 2002, 58(Suppl 5):S2-S8.
13. Brooks-Kayal A.R., Bath K.G., Berg A.T., Galanopoulou A.S., Holmes G.L., Jensen F.E., Kanner A.M., O'Brien T.J., Whittemore V.H., Winawer M.R., et al. Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 2013, 54(Suppl 4):44-60.
14. Cameron W.B. Informal Sociology: A Casual Introduction to Sociological Thinking 1963, Random house, New York.
15. Cedernaes J., Schiöth H.B., Benedict C. Efficacy of antibody-based therapies to treat Alzheimer's disease: just a matter of timing?. Exp. Gerontol. 2014, 57:104-106.
16. Coleman B.R., Ratcliffe R.H., Oguntayo S.A., Shi X., Doctor B.P., Gordon R.K., Nambiar M.P. [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. Chem. Biol. Interact. 2008, 175:387-395.
17. Cook R.J., Sackett D.L. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995, 310:452-454.
18. Cunha A.O., Mortari M.R., Liberato J.L., dos Santos W.F. Neuroprotective effects of diazepam, carbamazepine, phenytoin and ketamine after pilocarpine-induced status epilepticus. Basic Clin. Pharmacol. Toxicol. 2009, 104:470-477.
19. D'Ambrosio R., Eastman C.L., Darvas F., Fender J.S., Verley D.R., Farin F.M., Wilkerson H.W., Temkin N.R., Miller J.W., Ojemann J., et al. Mild passive focal cooling prevents epileptic seizures after head injury in rats. Ann. Neurol. 2013, 73:199-209.
20. Dash P.K., Orsi S.A., Zhang M., Grill R.J., Pati S., Zhao J., Moore A.N. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS ONE 2010, 5:e11383.
21. Detrait E.R., Leclercq K., Löscher W., Potschka H., Niespodziany I., Hanon E., Kaminski R.M., Matagne A., Lamberty Y. Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats. Epilepsy Res. 2010, 91:74-83.
22. Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S., Kieburtz K., Raman R., Sun X., Aisen P.S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N.Engl. J. Med. 2014, 370:311-321. Alzheimer's Disease Cooperative Study Steering Committee, Solanezumab Study GroupSolanezumab Study Group.
23. Driver-Dunckley E., Adler C.H., Hentz J.G., Dugger B.N., Shill H.A., Caviness J.N., Sabbagh M.N., Beach T.G. Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. Parkinsonism Relat. Disord. 2014, the Arizona Parkinson Disease Consortium, Published online August 16, 2014. 10.1016/j.parkreldis.2014.08.006.
24. Eddy C.M., Rickards H.E., Cavanna A.E. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord 2011, 4:385-407.
25. Engel J. Biomarkers in epilepsy: introduction. Biomarkers Med. 2011, 5:537-544.
26. Fisher M., Feuerstein G., Howells D.W., Hurn P.D., Kent T.A., Savitz S.I., Lo E.H., Group S. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250. STAIR Group.
27. Franco R., Cedazo-Minguez A. Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?. Front Pharmacol 2014, 5:146.
28. Galanopoulou A.S. Basic mechanisms of catastrophic epilepsy - overview from animal models. Brain Dev. 2013, 35:748-756.
29. Galanopoulou A.S., Simonato M., French J.A., O'Brien T.J. Joint AES/ILAE translational workshop to optimize preclinical epilepsy research. Epilepsia 2013, 54(Suppl 4):1-2.
30. Gomes W.A., Shinnar S. Prospects for imaging-related biomarkers of human epileptogenesis: a critical review. Biomarkers Med. 2011, 5:599-606.
31. Gordon P.H. Advances in clinical trials for amyotrophic lateral sclerosis. Curr. Neurol. Neurosci. Rep. 2005, 5:48-54.
32. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6:1045-1053. Western ALS Study Group.
33. Gordon P.H., Cheung Y.K., Levin B., Andrews H., Doorish C., Macarthur R.B., Montes J., Bednarz K., Florence J., Rowin J., et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph. Lateral Scler. 2008, 9:212-222. Combination Drug Selection Trial Study Group.
34. Halford J.J., Ben-Menachem E., Kwan P., Ness S., Schmitt J., Eerdekens M., Novak G. A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia 2011, 52:816-825.
35. Hermann B., Meador K.J., Gaillard W.D., Cramer J.A. Cognition across the lifespan: antiepileptic drugs, epilepsy, or both?. Epilepsy Behav. 2010, 17:1-5.
36. Hesdorffer D.C., Shinnar S., Lewis D.V., Moshé S.L., Nordli D.R., Pellock J.M., MacFall J., Shinnar R.C., Masur D., Frank L.M., et al. Design and phenomenology of the FEBSTAT study. Epilepsia 2012, 53:1471-1480. FEBSTAT study team.
37. Ijff D.M., Aldenkamp A.P. Cognitive side-effects of antiepileptic drugs in children. Handb. Clin. Neurol. 2013, 111:707-718.
38. Jequier Gygax M., Klein B.D., White H.S., Kim M., Galanopoulou A.S. Efficacy and tolerability of the galanin analog NAX 5055 in the multiple-hit rat model of symptomatic infantile spasms. Epilepsy Res. 2014, 108:98-108.
39. * 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review. Ther Adv Drug Saf 2013, 4:246-253.
40. Katsuno M., Tanaka F., Sobue G. Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. J.Neurol. Neurosurg. Psychiatry 2012, 83:329-335.
41. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004, 1:189-195.
42. Kelley M.S., Jacobs M.P., Lowenstein D.H., Stewards N.E.B. The NINDS epilepsy research benchmarks. Epilepsia 2009, 50:579-582. NINDS Epilepsy Benchmark Stewards.
43. Klitgaard H., Verdru P. Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov 2007, 2:1537-1545.
44. Klitgaard H., Matagne A., Gobert J., Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998, 353:191-206.
45. Kobayashi D.T., Chen K.S. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav. 2005, 4:173-196.
46. Koepp M.J. Hippocampal sclerosis: cause or consequence of febrile seizures. J.Neurol. Neurosurg. Psychiatry 2000, 69:716-717.
47. Krauss G.L., Perucca E., Ben-Menachem E., Kwan P., Shih J.J., Clément J.F., Wang X., Bagul M., Gee M., Zhu J., Squillacote D. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia 2014, 55:1058-1068.
48. Kwan J. Stroke: predicting the risk of poststroke epilepsy-why and how?. Nat Rev Neurol 2010, 6:532-533.
49. Lanthier M., Miller K.L., Nardinelli C., Woodcock J. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Health Aff. (Millwood) 2013, 32:1433-1439.
50. Lebouvier T., Neunlist M., Bruley des Varannes S., Coron E., Drouard A., N'Guyen J.M., Chaumette T., Tasselli M., Paillusson S., Flamand M., et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS ONE 2010, 5:e12728.
51. Lewis D.V., Shinnar S., Hesdorffer D.C., Bagiella E., Bello J.A., Chan S., Xu Y., MacFall J., Gomes W.A., Moshé S.L., et al. Hippocampal sclerosis after febrile status epilepticus: the FEBSTAT study. Ann. Neurol. 2014, 75:178-185. FEBSTAT Study Team.
52. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011, 20:359-368.
53. Lowenstein D.H. Interview: the National Institute of Neurological Diseases and Stroke/American Epilepsy Society benchmarks and research priorities for epilepsy research. Biomarkers Med. 2011, 5:531-535.
54. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
55. McAlister F.A., Straus S.E., Guyatt G.H., Haynes R.B. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. JAMA 2000, 283:2829-2836. Evidence-Based Medicine Working Group.
56. Möller C. Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology. Expert Rev Clin Pharmacol 2010, 3:321-329.
57. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J.Neurosci. Methods 1984, 11:47-60.
58. Murphy G.G. Spatial Learning and Memory-What's TLE Got To Do With It?. Epilepsy Curr. 2013, 13:26-29.
59. Novak G.P., Kelley M., Zannikos P., Klein B. Carisbamate (RWJ-333369). Neurotherapeutics 2007, 4:106-109.
60. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
61. Perrin S. Preclinical research: Make mouse studies work. Nature 2014, 507:423-425.
62. Pinna A. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 2014, 28:455-474.
63. Redfern W.S., Ewart L.C., Lainee P., Pinches M., Robinson S., Valentin J.P. Functional assessments in repeat-dose toxicity studies: the art of the possible. Toxicol. Res. 2013, 2:209-234.
64. Samsonsen C., Reimers A., Bråthen G., Helde G., Brodtkorb E. Nonadherence to treatment causing acute hospitalizations in people with epilepsy: An observational, prospective study. Epilepsia 2014.
65. Schmidt D., Friedman D., Dichter M.A. Anti-epileptogenic clinical trial designs in epilepsy: issues and options. Neurotherapeutics 2014, 11:401-411.
66. Schneider B.M., Dodman N.H., Faissler D., Ogata N. Clinical use of an herbal-derived compound (Huperzine A) to treat putative complex partial seizures in a dog. Epilepsy Behav. 2009, 15:529-534.
67. Sharrad D.F., de Vries E., Brookes S.J. Selective expression of α-synuclein-immunoreactivity in vesicular acetylcholine transporter-immunoreactive axons in the guinea pig rectum and human colon. J.Comp. Neurol. 2013, 521:657-676.
68. Shinnar S. Febrile Seizures and Mesial Temporal Sclerosis. Epilepsy Curr. 2003, 3:115-118.
69. Shinnar S., Bello J.A., Chan S., Hesdorffer D.C., Lewis D.V., Macfall J., Pellock J.M., Nordli D.R., Frank L.M., Moshe S.L., et al. MRI abnormalities following febrile status epilepticus in children: the FEBSTAT study. Neurology 2012, 79:871-877. FEBSTAT Study Team.
70. Steinhoff B.J., Hamer H., Trinka E., Schulze-Bonhage A., Bien C., Mayer T., Baumgartner C., Lerche H., Noachtar S. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res. 2014, 108:986-988.
71. Stewart K.A., Wilcox K.S., Fujinami R.S., White H.S. Development of postinfection epilepsy after Theiler's virus infection of C57BL/6 mice. J.Neuropathol. Exp. Neurol. 2010, 69:1210-1219.
72. Tonduli L.S., Testylier G., Masqueliez C., Lallement G., Monmaur P. Effects of Huperzine used as pre-treatment against soman-induced seizures. Neurotoxicology 2001, 22:29-37.
73. Verity C.M., Golding J. Risk of epilepsy after febrile convulsions: a national cohort study. BMJ 1991, 303:1373-1376.
74. Vosoughi R., Freedman M.S. Therapy of MS. Clin. Neurol. Neurosurg. 2010, 112:365-385.
75. Wenk G.L. Assessment of spatial memory using the radial arm maze and Morris water maze. Curr. Protoc. Neurosci. 2004, Chapter 8:5A.
76. White H.S., Löscher W. Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies. Neurotherapeutics 2014, 11:373-384.
77. White H.S., Alex A.B., Pollock A., Hen N., Shekh-Ahmad T., Wilcox K.S., McDonough J.H., Stables J.P., Kaufmann D., Yagen B., Bialer M. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012, 53:134-146.
78. Zangara A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol. Biochem. Behav. 2003, 75:675-686.
79. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu D.C., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417:74-78.